Gruss Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Gruss Capital Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-184,333	Closed	-$1.41M	–	59
2016 Q1	$1.41M	Hold	184,333	–	–	0.04%	43
2015 Q4	$2.46M	Hold	184,333	–	–	0.08%	67
2015 Q3	$3.03M	Hold	184,333	–	–	0.1%	63
2015 Q2	$4.14M	Hold	184,333	–	–	0.15%	47
2015 Q1	$1.8M	Buy	184,333 +16,833	+10%	+$165K	0.07%	63
2014 Q4	$1.91M	Buy	167,500 +17,500	+12%	+$190K	0.05%	76
2014 Q3	$1.73M	Buy	+150,000	New	+$2.29M	0.08%	58

Other funds holding CASC

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Gruss Capital Management's CASC Position: Q2 2016 in Review

Gruss Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2016, closing a stake of 184,333 shares — an estimated $1.41M sold.

Gruss Capital Management first reported a position in CASC in Q3 2014 and held it in 7 quarters. The position peaked at $4.14M in Q2 2015. 75 funds tracked by Wall St. Rank hold CASC as of Q2 2016.

Gruss Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Gruss Capital Management sold 184,333 Cascadian Therapeutics, Inc. shares in Q2 2016, an estimated $1.41M.
Gruss Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2014 and held it in 7 quarters.
Gruss Capital Management's Cascadian Therapeutics, Inc. position peaked at $4.14M in Q2 2015.
75 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2016.

Based on Gruss Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.